BioSig Technologies (NASDAQ: BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(TM) noise-filtering technology. According to the update, the recently allowed patent application number 17/082,564, entitled, “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (‘EP’) SIGNAL PROCESSING ” was filed on October 28, 2020. “We are pleased to announce this newest patent allowance, which demonstrates the clinical significance of our PURE EP(TM) System in filtering noise from complex cardiac signals in the electrophysiological setting,” said Kenneth L. Londoner, chairman and CEO of BioSig Technologies. “The industry reports consistently indicate that inability to detect small intracardiac signals and difficulties to record high-quality signals account for some of the main factors that interfere with effective cardiac ablations. We believe that we have the leading patent-protected solution for ensuring signal clarity that is paramount to the success of cardiac ablations for all types of cardiac arrhythmias.”
To view the full press release, visit https://ibn.fm/OMGCR
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The company’s first product, PURE EP(TM) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (“EP”) procedures in an EP laboratory. For more information about the company, visit www.BioSig.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.